Drug Development: Protease Inhibitors: A Tale of Two Companies

See allHide authors and affiliations

Science  28 Jun 1996:
Vol. 272, Issue 5270, pp. 1882-1883
DOI: 10.1126/science.272.5270.1882

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


A new class of anti-HIV drugs called protease inhibitors offers the most promising therapy so far. In combination with other antiviral drugs, they can reduce virus loads to undetectable levels. The manufacturers of the two leading protease inhibitors, Merck and Abbott, took different routes but arrived at the finishing post at almost exactly the same time.

View Full Text

Stay Connected to Science

Editor's Blog